Behind the Scams | AI Scams & Digital Deception Experts

Theranos Scam Analysis: How Elizabeth Holmes Misled Investors Using Fake Tech and Borrowed Credibility

42 min Listen to the original Episode page
FraudHealthcareVenture CapitalDue DiligenceLegal VerdictsCorporate GovernanceInvestment Scams

Summary

The hosts analyze the Theranos scandal as a case study in investment fraud, detailing how Elizabeth Holmes misled investors about the company's proprietary blood-testing technology. They highlight that while Theranos claimed to perform over 200 tests from a few drops of blood, its device only handled about 12, with the rest run on modified commercial analyzers. The episode outlines how Holmes used unauthorized logos of Pfizer and Schering-Plow, fabricated military deployment claims, and high-profile investor backing to create false social proof and credibility. Legal outcomes are reviewed, noting Holmes was convicted of investor fraud but acquitted of patient-related charges, while co-founder Ramesh Balwani was convicted on all counts. The speakers conclude with a verification checklist for investors to detect similar deception tactics.

Episode sections

  1. 0:40 – 2:07

    Introduction and Scam Mechanics

    Hosts introduce Theranos as a case study in con games, focusing on borrowing credibility and creating scarcity.

  2. 2:07 – 4:26

    The Technology Promise vs. Reality

    SEC allegations that investors were misled about the analyzer's capabilities, which only performed ~12 of 200+ tests.

  3. 4:26 – 5:33

    Sample Quality and Verification Challenges

    Discussion of technical difficulties in finger-stick testing and WHO warnings about hemolysis and contamination.

  4. 5:33 – 8:13

    The 'Bait and Switch' Demonstration

    Holmes admitted to using modified Siemens analyzers; Erica Chung testified samples were secretly processed at Normandy lab.

  5. 8:13 – 11:10

    Misuse of Corporate Logos

    Holmes added unauthorized Pfizer and Schering-Plow logos to reports, creating a false impression of validation.

  6. 11:10 – 12:13

    Financial Discrepancies and Valuation

    SEC reported promised $100M+ revenue vs. actual ~$100k; clarified $9B valuation was equity estimate, not cash.

  7. 12:13 – 18:14

    Investor Profile and Social Proof

    Theranos raised $700M+ from Walton, Murdoch, and DeVos families, using social proof to discourage due diligence.

  8. 18:14 – 32:35

    Board Authority and Military Claims

    Board included former Secretaries of State and Generals; SEC alleged false claims of DoD deployment in Afghanistan.

  9. 32:35 – 34:18

    Legal Verdicts and Sentencing

    Holmes convicted of investor fraud (135 months); Balwani convicted on all counts including patient fraud (155 months).

  10. 34:18 – 36:11

    Scam Tactics Checklist

    Five tactics identified: unauthorized logos, concealed tech, exclusive access, fabricated military track record, suppressing info.

  11. 36:11 – 37:27

    The Black Turtleneck and Steve Jobs Comparison

    Holmes wore black turtlenecks to reduce decision fatigue; speakers caution against mistaking image for legitimacy.

  12. 37:27 – 42:12

    Verification Checklist for Investors

    Four checks: verify device results, distinguish partnerships from validation, demand evidence for endorsements, review QC data.

Claims worth verifying

Theranos' proprietary analyzer performed only approximately 12 of the more than 200 tests on its published patient menu.

Unidentified speaker ·3:46

How to verify: Review the SEC complaint filed against Elizabeth Holmes and Ramesh Balwani, specifically sections detailing the scope of the Edison device's capabilities versus the marketed menu.

Holmes admitted on the witness stand that she added Pfizer and Shering-Plow logos to Theranos' reports without authorization.

Unidentified speaker ·8:24

How to verify: Review trial transcripts or court filings from the United States v. Elizabeth Holmes case regarding the admission of unauthorized logo usage.

Actual revenue from operations in 2014 was a little more than $100,000, while investors were told Theranos would generate more than $100 million.

Unidentified speaker ·11:14

How to verify: Compare SEC filings or trial testimony regarding Theranos' financial statements against the investor presentations or pitch decks cited in the SEC complaint.

Theranos raised more than $700 million from late 2013 through 2015.

Unidentified speaker ·12:20

How to verify: Review the SEC complaint or court documents detailing the fundraising rounds and total capital raised during this period.

The DeVos family invested $100 million, the Walton family $150 million, and Rupert Murdoch $125 million.

Unidentified speaker ·12:40

How to verify: Review court documents or trial reporting cited in the transcript that identify specific investment amounts from these families.

Theranos was privately valued at $9 billion, with Holmes' ownership stake worth as much as $4.5 billion on paper.

Unidentified speaker ·13:24

How to verify: Review financial reporting from CNBC or other outlets covering the trial that cited the company's valuation figures.

Theranos burned roughly $2 million a week in cash by 2013, with an accumulated deficit of $575 million by 2015.

Unidentified speaker ·14:42

How to verify: Review trial testimony from former controller Denise Ames as reported in court documents or news coverage of the trial.

The SEC said Theranos claimed its products were deployed by the Department of Defense on battlefields in Afghanistan and on medical evacuation helicopters, but this deployment had never happened.

Unidentified speaker ·19:02

How to verify: Review the SEC complaint or trial testimony regarding false claims about military deployment of Theranos technology.

Erica Chung testified that Edison machines frequently failed quality control checks and that data points were deleted to make results appear to pass.

Unidentified speaker ·26:21

How to verify: Review trial transcripts or court filings detailing Erica Chung's testimony regarding laboratory quality control procedures.

Holmes acknowledged going to Rupert Murdoch to try to stop the Wall Street Journal's reporting.

Unidentified speaker ·29:50

How to verify: Review trial transcripts or court filings detailing Holmes' cross-examination regarding her interactions with Rupert Murdoch and the Wall Street Journal.

Elizabeth Holmes was convicted of one investor fraud conspiracy count and three investor wire fraud counts, and acquitted on patient-related conspiracy and individual patient counts.

Unidentified speaker ·32:40

How to verify: Review the January 2022 federal court verdict records for United States v. Holmes.

Ramesh Balwani was convicted on all 12 counts, including two conspiracy counts (one for investors, one for patients) and ten wire fraud counts (six for investors, four for patients).

Unidentified speaker ·32:57

How to verify: Review the July 7, 2022 federal court verdict records for United States v. Balwani.

Ramesh Balwani was sentenced to 155 months in federal prison on December 7, 2022.

Unidentified speaker ·33:22

How to verify: Review the December 7, 2022 sentencing documents for United States v. Balwani.

Elizabeth Holmes was originally sentenced to 135 months in federal prison on November 18, 2022.

Unidentified speaker ·33:39

How to verify: Review the November 18, 2022 sentencing documents for United States v. Holmes.

Dr. Ian Gibbons, Theranos' chief scientist, died by suicide in 2013.

Unidentified speaker ·31:20

How to verify: Review public records or news reports from 2013 regarding the death of Ian Gibbons.

Brittany Gould testified that Theranos' pregnancy hormone results led her clinician to tell her she was miscarrying, but she later had a healthy baby.

Unidentified speaker ·31:53

How to verify: Review trial transcripts or news reports from the Theranos trial regarding patient testimony.

Erin Tompkins testified about an abnormal HIV antibody result from Theranos that was later found to be negative upon retesting.

Unidentified speaker ·32:13

How to verify: Review trial transcripts or news reports from the Theranos trial regarding patient testimony.

Holmes acknowledged using modified Siemens analyzers without telling partners.

Unidentified speaker ·34:46

How to verify: Review trial transcripts or news reports detailing Holmes' admissions regarding the technology used.

Holmes claimed a military deployment track record that never happened.

Unidentified speaker ·35:15

How to verify: Review SEC filings or trial evidence regarding Theranos' marketing claims about military use.

Former Theranos designer Anna Areola described Holmes' admiration for Steve Jobs' uniform and interest in achieving a similar look.

Unidentified speaker ·36:56

How to verify: Review trial transcripts or news reports regarding Anna Areola's testimony about Holmes' attire.

Do your own research

  • Verify the specific capabilities of proprietary technology against the full menu of advertised tests using SEC filings or court documents.
  • Distinguish between business partnerships and independent technical validation by checking for authorized use of partner logos or endorsements.
  • Demand full quality control data, including records of failed tests, rather than relying solely on successful demo results.
  • Investigate the source of prestigious endorsements (e.g., military or institutional) to confirm they are factual and not fabricated.
  • Review the valuation methodology for private companies to understand that high valuations do not equate to available cash or revenue.
  • Check for conflicts of interest among investors, such as those who may also own media outlets covering the company.
  • Assess the credibility of the board and advisors, noting that borrowed authority from high-profile figures does not validate technical claims.
  • Look for whistleblower testimony or internal communications that contradict public marketing materials, such as the testimony of Erica Chung.
Full transcriptexpand
0:00
Unidentified speaker: Welcome to Behind the Scamps.
0:01
Unidentified speaker: I'm Nick, and I'm here with my wife and co-host Sue.
0:04
Unidentified speaker: We've got a real good episode today.
0:06
Unidentified speaker: Like everyone else in the world, you know that former startup queen, Elizabeth Holmes, and the Therono scandal are back in the news.
0:13
Unidentified speaker: Seems like everyone is talking about the new documentary, You Can See Everything.
0:17
Unidentified speaker: Of course, I've heard of it.
0:19
Unidentified speaker: You have to have been living underneath a rock to not know about that one.
0:23
Unidentified speaker: And I'd also like to remind you that you've been promising to take me to that movie since it came out.
0:30
Unidentified speaker: Your Honor, this is irrelevant.
0:32
Unidentified speaker: Sustained.
0:34
Unidentified speaker: Thank you.
0:34
Unidentified speaker: And I promise I'll take you.
0:36
Unidentified speaker: Good.
0:37
Unidentified speaker: I'm keeping that promise on the record.
0:39
Unidentified speaker: Fair enough.
0:40
Unidentified speaker: But there are two reasons I want to revisit this old Tilicon Valley tale.
0:44
Unidentified speaker: First, the documentary has brought Holmes and Theranos back into the conversation.
0:50
Unidentified speaker: Second, this was a huge scam built on familiar con games.
0:54
Unidentified speaker: Borrowing credibility, making people afraid they'll miss out, dressing claims up as proof, and shutting down questions.
1:01
Unidentified speaker: Those same pressures still matter today.
1:03
Unidentified speaker: So the documentary is the reason it's back in the headlines.
1:07
Unidentified speaker: The scam itself is the reason it's worth talking about again.
1:10
Unidentified speaker: The scale was extraordinary.
1:13
Unidentified speaker: Many of the tricks were familiar.
1:15
Unidentified speaker: That's what makes the story compelling and useful beyond Silicon Valley.
1:18
Unidentified speaker: So we're not treating homes like some mysterious exception to the rules.
1:23
Unidentified speaker: We're asking a simpler question.
1:25
Unidentified speaker: What were people promised?
1:26
Unidentified speaker: What did they actually get?
1:27
Unidentified speaker: And how did the gap stay hidden?
1:30
Unidentified speaker: Because if we spend the whole episode asking how a famous person fooled billionaires, we miss the part that matters to the rest of us.
1:37
Unidentified speaker: What does the same sales pitch sound like when it arrives in our inbox?
1:42
Unidentified speaker: Comes from someone we trust or offers something our family really needs.
1:46
Unidentified speaker: That's the heart of it.
1:48
Unidentified speaker: Everyday scam mechanics operating at corporate scale.
1:51
Unidentified speaker: A black turtleneck doesn't create a special category of fraud.
1:55
Unidentified speaker: And wanting cheaper, easier health care doesn't make a person foolish.
2:00
Unidentified speaker: That was a genuinely appealing promise.
2:02
Unidentified speaker: The responsibility for deception belongs to the people doing the deceiving.
2:07
Unidentified speaker: Let's put some substance behind that promise.
2:09
Unidentified speaker: The SEC said investors were led to believe Theranos had developed a proprietary analyzer that could perform a comprehensive range of laboratory tests from a few drops of blood.
2:20
Unidentified speaker: The pitch was faster results, lower costs, and greater accuracy than conventional laboratories.
2:26
Unidentified speaker: That reaches people in two different places.
2:28
Unidentified speaker: An investor hears an enormous business opportunity.
2:31
Unidentified speaker: A patient hears maybe getting the care I need won't be so expensive or unpleasant.
2:37
Unidentified speaker: Exactly.
2:38
Unidentified speaker: It's easier to believe a promise when you really want it to be true.
2:43
Unidentified speaker: That's how we read the appeal here.
2:45
Unidentified speaker: But wanting better health care and knowing this machine could deliver it are two different things.
2:51
Unidentified speaker: And there's nothing wrong with that hope.
2:53
Unidentified speaker: The question is whether you can ask, does it work without being made to feel you're against helping people?
2:59
Unidentified speaker: As we go, we'll put names to some of these tricks.
3:03
Unidentified speaker: Borrowed authority, social proof, scarcity.
3:06
Unidentified speaker: They're familiar ideas and persuasion.
3:08
Unidentified speaker: We're using them to explain what the evidence shows, not pretending we know everything Holmes is thinking.
3:14
Unidentified speaker: Because convincing someone isn't automatically dishonest.
3:17
Unidentified speaker: The trouble starts when a convincing story stands in for proof.
3:21
Unidentified speaker: The distinction is between we hope to build this and this is what our product does now.
3:27
Unidentified speaker: A research goal can be ambitious.
3:30
Unidentified speaker: A description of an operating medical service has to match reality.
3:34
Unidentified speaker: So the promise wasn't just a smaller needle.
3:37
Unidentified speaker: Could people trust the results?
3:39
Unidentified speaker: And could Theranos' own machine really deliver the whole menu?
3:43
Unidentified speaker: The SEC complaint gives us an important comparison.
3:46
Unidentified speaker: Theranos had more than 200 tests on its published patient menu, but its proprietary analyzer performed only approximately 12 of them in its clinical laboratory.
3:57
Unidentified speaker: The remainder were processed on commercial analyzers, some modified for finger stick samples.
4:03
Unidentified speaker: So a long menu didn't mean their machine could run all those tests.
4:06
Unidentified speaker: Does that approximately 12 figure tell us whether the results were reliable?
4:12
Unidentified speaker: Right, and that approximately 12 figure is about which tests the device performed.
4:18
Unidentified speaker: It doesn't establish that all 12 were consistently accurate.
4:22
Unidentified speaker: We have to keep capability and reliability separate.
4:26
Unidentified speaker: Then the question is, what can this particular device do?
4:29
Unidentified speaker: Not just what does the company offer, how does the blood sample itself fit into that?
4:34
Unidentified speaker: We also need to be fair about finger brick testing.
4:37
Unidentified speaker: It's legitimate for appropriate tests.
4:39
Unidentified speaker: The World Health Organization describes how collection technique matters, including how excessive squeezing can introduce tissue fluid, increase the risk of hemolysis.
4:48
Unidentified speaker: The problem isn't that every small sample test is impossible, it's that a sweeping claim needs test-specific evidence.
4:56
Unidentified speaker: Hemolysis means blood cells breaking open, tissue fluid contamination is a different problem.
5:01
Unidentified speaker: Those are sample quality issues, and neither disappears because a company has a persuasive founder.
5:07
Unidentified speaker: In plain English, the machine needs a usable sample, not just a little red liquid.
5:12
Unidentified speaker: And smaller doesn't automatically mean better.
5:16
Unidentified speaker: A product failing doesn't by itself establish fraud.
5:19
Unidentified speaker: The question is whether people were told a truth about what existed, what worked, and what was still experimental.
5:33
Unidentified speaker: Alright, let's follow the test.
5:35
Unidentified speaker: If another company's equipment is doing the work, where does the legitimate workaround become a bait and switch?
5:41
Unidentified speaker: Using someone else's laboratory equipment isn't automatically wrongdoing.
5:46
Unidentified speaker: The deception is representing one process while delivering another, especially when the claim process is central to the investment.
5:54
Unidentified speaker: You're buying the breakthrough, not a familiar machine behind a curtain with a new story attached.
6:00
Unidentified speaker: In her trial testimony, Holmes acknowledged using modified Siemens analyzers.
6:05
Unidentified speaker: She said the modifications were inventions Theranos wanted to protect as trade secrets.
6:11
Unidentified speaker: That was her explanation for not telling partners about them.
6:15
Unidentified speaker: That's the bait and switch.
6:16
Unidentified speaker: People were backing a breakthrough.
6:19
Unidentified speaker: If ordinary equipment was doing the work and they weren't told, they couldn't judge what Theranos had actually built.
6:24
Unidentified speaker: And is calling it a trade secret shift the conversation?
6:28
Unidentified speaker: You ask, what did the test, and suddenly you're discussing why a valuable secret needs protecting?
6:33
Unidentified speaker: It can.
6:34
Unidentified speaker: That's why you bring it back to the process.
6:36
Unidentified speaker: Seeing blood collected, a cartridge inserted, and a report delivered later doesn't show what happened in between.
6:43
Unidentified speaker: You need evidence connecting the sample, the instrument, and the result.
6:47
Unidentified speaker: Otherwise, you've watched the beginning and the end of a process and supplied the middle yourself.
6:52
Unidentified speaker: Erica Chung described what happened behind the demonstration.
6:55
Unidentified speaker: The former Theranos employee testified that a finger prick was followed by a cartridge going into an Edison device.
7:02
Unidentified speaker: Employees then stood ready to remove it and take it downstairs to the lab called Normandy, where modified third-party machines tested the small sample.
7:12
Unidentified speaker: That gives us a concrete account alongside the SEC's allegation of misleading technology demonstration.
7:18
Unidentified speaker: So the visitor sees the device and gets results, but doesn't see the part that would change the whole story.
7:24
Unidentified speaker: That's what her account describes.
7:26
Unidentified speaker: The demonstration links the result to the visible device in the visitor's mind, even though different equipment did the work.
7:33
Unidentified speaker: That's more than making a product look attractive.
7:36
Unidentified speaker: You're giving somebody a reason to say, I watched it work.
7:40
Unidentified speaker: That's right.
7:40
Unidentified speaker: It's misdirection through a managed experience.
7:44
Unidentified speaker: A result can be real and still be used to support a false explanation of how it was obtained.
7:49
Unidentified speaker: That's why verifying the entire process matters.
7:52
Unidentified speaker: But if you were there and they took you blood, wouldn't you feel you checked it yourself?
7:58
Unidentified speaker: What do you look for when that feeling of proof carries over into the paperwork?
8:03
Unidentified speaker: With paperwork, my financial crime background is useful.
8:06
Unidentified speaker: I want to know who created the document, who approved it, what it establishes, and what the recipient was led to believe.
8:13
Unidentified speaker: A logo is not independent validation.
8:16
Unidentified speaker: So who's actually speaking through that letterhead?
8:19
Unidentified speaker: What happened with the pharmaceutical company logos?
8:22
Unidentified speaker: Here's the concrete document issue.
8:24
Unidentified speaker: Holmes admitted on the witness stand that she added Pfizer and uh Sharing Plow logos to Therno's reports.
8:31
Unidentified speaker: Witnesses from those companies testified that the logos had not been authorized.
8:35
Unidentified speaker: Holmes said she meant to reflect work done in partnership and denied intending to suggest the companies had written the reports.
8:43
Unidentified speaker: Yeah, which just doesn't fly with a jury when you've got this long trail of actual corporate executives lined up to call her a fraud.
8:50
Unidentified speaker: That's her explanation.
8:53
Unidentified speaker: But what would a recipient reasonably take those logos to mean?
8:57
Unidentified speaker: Right.
8:57
Unidentified speaker: Prosecutors argue that those reports made the technology look independently validated by the drug companies.
9:04
Unidentified speaker: It's borrowed authority.
9:05
Unidentified speaker: The logo makes it look as though a name you trust is vouching for the claim.
9:10
Unidentified speaker: So it's not just trust us, it looks like these people checked us.
9:15
Unidentified speaker: That's a very different message.
9:17
Unidentified speaker: It's the same verification problem in an advanced fee or investment pitch that uses a bank's logo.
9:24
Unidentified speaker: Who created the document?
9:26
Unidentified speaker: What did the named institution actually confirm?
9:29
Unidentified speaker: You verify with that institution through a channel you choose, not just through the person selling the deal.
9:35
Unidentified speaker: And what about the retailers?
9:37
Unidentified speaker: Seeing a medical service in a familiar pharmacy would make it feel less like an untested startup.
9:42
Unidentified speaker: Walgreens and Safeway were important parts of the story.
9:46
Unidentified speaker: Reporting on trial testimony described Walgreens finance executive, Wade Mikelon, saying the outside review involved interpreting data Feranos applied rather than taking the machine apart.
9:58
Unidentified speaker: Experts consulted by the retailers considered the idea sound, without getting their hands on the device to test it themselves.
10:05
Unidentified speaker: So an opinion about the idea could be mistaken for proof that the actual product worked.
10:11
Unidentified speaker: That's the distinction.
10:13
Unidentified speaker: Evaluating a concept, reviewing the seller's selected information, and independently testing a working device are different levels of scrutiny.
10:22
Unidentified speaker: A psychological shortcut is treating them as though they're the same.
10:26
Unidentified speaker: And once a familiar retailer offers it, a customer can reasonably think, surely somebody checked this before putting it here.
10:34
Unidentified speaker: That's how a partnership can pass credibility along.
10:37
Unidentified speaker: But we shouldn't assume from that alone what every executive knew.
10:41
Unidentified speaker: Walgreens began offering Theranos testing in 2013 and ended the partnership in 2016.
10:49
Unidentified speaker: The lesson is to ask what the partnership actually establishes, not to treat a recognizable storefront as scientific validation.
10:57
Unidentified speaker: It's another version of borrowed trust.
11:00
Unidentified speaker: The store's reputation makes the service feel established before the customer ever asks about the test.
11:05
Unidentified speaker: A logo can be copied in seconds.
11:08
Unidentified speaker: Its credibility took years to build.
11:10
Unidentified speaker: What about the financial picture?
11:12
Unidentified speaker: Did the revenue match the pitch?
11:14
Unidentified speaker: The SEC said investors were told Theranos would generate more than $100 million in revenue in 2014.
11:21
Unidentified speaker: Actual revenue from operations that year was a little more than $100,000.
11:27
Unidentified speaker: Those aren't slightly different business pictures, but how do you distinguish a failed forecast from fraud?
11:33
Unidentified speaker: And a forecast missing its target doesn't automatically prove fraud.
11:37
Unidentified speaker: The issue is what the projection was based on, and whether investors were also misled about the company's existing technology, partnerships, and business.
11:47
Unidentified speaker: To me, that's the pull.
11:49
Unidentified speaker: Tomorrow looks so exciting that you stop asking what's happening today.
11:53
Unidentified speaker: Everybody's talking about the big number instead of what supports it.
11:57
Unidentified speaker: Which is why we separate money raised from customers' payments and both from expected future revenue.
12:04
Unidentified speaker: A company receiving investment money is not proof its product is producing the business results it promised.
12:10
Unidentified speaker: Let's follow the money a little further.
12:13
Unidentified speaker: How much did Holmes actually persuade people to put into Theranos?
12:16
Unidentified speaker: We've mentioned the SEC's figure, but was that the whole amount?
12:20
Unidentified speaker: No.
12:20
Unidentified speaker: The SEC described more than $700 million raised from late 2013 through 2015.
12:26
Unidentified speaker: CNBC's reporting on the trial put the broader total invested in Theranos at more than $900 million.
12:32
Unidentified speaker: Those figures cover different scopes.
12:34
Unidentified speaker: Neither means Holmes personally received that amount in her bank account.
12:37
Unidentified speaker: And these weren't just small tracks from a lot of people.
12:40
Unidentified speaker: Court document reporting identified $150 million from the Walton family, $125 million from Rupert Murdoch, and $100 million from the DeVoth family.
12:52
Unidentified speaker: Those commitments made Theranos look exceptionally well-packed.
12:56
Unidentified speaker: We'll come back to how the DeVoth investment grew after the meeting with Holmes.
13:01
Unidentified speaker: Which creates another temptation.
13:03
Unidentified speaker: If they put that much in, they must know something I don't.
13:07
Unidentified speaker: Exactly.
13:08
Unidentified speaker: But the amount someone invests tells you the size of their commitment, not the quality of their evidence.
13:14
Unidentified speaker: Another investor's confidence can become a substitute for your own verification.
13:18
Unidentified speaker: And the famous $9 billion valuation, was that money the company had?
13:23
Unidentified speaker: No.
13:24
Unidentified speaker: Reporting described Theranos as privately valued at $9 billion, and home's ownership stake as worth as much as $4.5 billion on paper.
13:34
Unidentified speaker: A valuation is an estimate of what ownership is worth.
13:38
Unidentified speaker: It's not cash available to pay the bills, and it isn't revenue from customers.
13:42
Unidentified speaker: Just to be clear, was Theranos a publicly traded company?
13:46
Unidentified speaker: No.
13:47
Unidentified speaker: Theranos was privately held and it never went public.
13:50
Unidentified speaker: That $9 billion figure was a private company valuation, not a value set by shares trading on a public stock exchange.
13:58
Unidentified speaker: So billionaire founder, hundreds of millions raised, and successful business aren't three ways of saying the same thing.
14:05
Unidentified speaker: Right.
14:06
Unidentified speaker: Keeping them separate helps us avoid mistaking the appearance of wealth for proof of a working product.
14:13
Unidentified speaker: Then where did the money go?
14:14
Unidentified speaker: Was it all paying for the lifestyle, or was there an actual company spending it?
14:19
Unidentified speaker: There was a real operation with research, laboratory work, equipment, employees, and corporate expenses.
14:27
Unidentified speaker: We don't have a complete audited breakdown that assigns every investment dollar to a category.
14:34
Unidentified speaker: What we can describe is the financial picture presented at trial and specific spending reported in the case.
14:40
Unidentified speaker: What did that picture show?
14:42
Unidentified speaker: Reporting on former controller Denise Am's testimony described Theranos burning roughly $2 million a week in cash by 2013.
14:51
Unidentified speaker: By 2015, she said its accumulated deficit had reached $575 million.
14:57
Unidentified speaker: An accumulated deficit is an accounting measure of losses over time, not a finding that somebody stole that amount.
15:04
Unidentified speaker: So the company could attract enormous investment and still be running through cash rather than supporting itself from its testing business.
15:13
Unidentified speaker: Yes.
15:14
Unidentified speaker: Holmes's lawyers argued that substantial research and development spending was normal for a startup, and that deferred revenue helped explain financial discrepancies.
15:24
Unidentified speaker: Research losses alone aren't fraud.
15:28
Unidentified speaker: The problem is whether investors are told the truth about the results, the remaining work and the risks.
15:34
Unidentified speaker: That gives we're still developing it a very different meaning from we've solved it and now we're expanding.
15:40
Unidentified speaker: Exactly.
15:41
Unidentified speaker: Yom also testified that the financial statements went unaudited for years.
15:46
Unidentified speaker: Separately, reporting describes rising legal costs, that Saranos face lawsuits and investigations.
15:52
Unidentified speaker: Money was being consumed by the business and its problems, not simply sitting behind that headline valuation.
15:59
Unidentified speaker: So the question isn't just how much have you raised, it's what did that money accomplish and what evidence shows it?
16:06
Unidentified speaker: Right, a large budget can fund real work.
16:09
Unidentified speaker: It can also keep an unsupported story going longer.
16:12
Unidentified speaker: Spending money on a problem doesn't prove you've solved it.
16:16
Unidentified speaker: But did Holmes really live lavishly?
16:19
Unidentified speaker: The black turtleneck suggests somebody too busy working to care about luxury.
16:23
Unidentified speaker: The lifestyle evidence was disputed in court.
16:26
Unidentified speaker: Prosecutors said their nose paid for private jet travel and expensive lodging, in addition to her salary.
16:32
Unidentified speaker: They also described company paid assistants handling personal errands and purchasing luxury goods.
16:38
Unidentified speaker: So the plain wardrobe wasn't a complete picture of the benefits she enjoyed.
16:43
Unidentified speaker: What did her lawyers say?
16:45
Unidentified speaker: They argued that her travel was overwhelmingly for company business, often encouraged or arranged by the board.
16:52
Unidentified speaker: They also stressed that she hadn't cashed out her shares and hadn't asked for a higher salary.
16:56
Unidentified speaker: That matters.
16:57
Unidentified speaker: Benefiting from company funded travel is different from selling billions of dollars of stock and pocketing the proceeds.
17:03
Unidentified speaker: So we shouldn't turn the paper billionaire into a story about billions in personal cash, but we also shouldn't assume she lived modestly because she dressed simply.
17:12
Unidentified speaker: Exactly.
17:13
Unidentified speaker: The judge allowed general evidence of executive benefits and status, but restricted references to particular luxury brands and purchases to avoid unfair prejudice.
17:24
Unidentified speaker: Wealth and expensive travel don't establish fraud.
17:28
Unidentified speaker: The underlying deception still has to be proved.
17:31
Unidentified speaker: And psychologically, the image can work both ways.
17:34
Unidentified speaker: Luxury can suggest success, while a plain uniform can suggest total devotion to the mission.
17:40
Unidentified speaker: Neither tells us whether the claims are true.
17:42
Unidentified speaker: Right.
17:43
Unidentified speaker: Prosecutors argue that celebrity, access to powerful people, and executive benefits gave her reasons to maintain the company's apparent success.
17:51
Unidentified speaker: That was their motive argument.
17:53
Unidentified speaker: Not permission for us to invent what she felt.
17:56
Unidentified speaker: Our practical question is whether the financial and scientific evidence supports the image.
18:01
Unidentified speaker: So follow the evidence, not the outfit.
18:04
Unidentified speaker: And don't confuse an impressive fundraising story with a business that can deliver.
18:08
Unidentified speaker: A spreadsheet can wear a convincing suit.
18:11
Unidentified speaker: It still needs numbers that come from somewhere.
18:14
Unidentified speaker: And beyond the paperwork, who was making this company look credible?
18:18
Unidentified speaker: Theranos' board included former Secretaries of State George Schultz and Henry Kissinger, retired Marine General James Mattis, retired Navy Admiral Gary Roged, and former senators Sam Nunn and William Frist.
18:32
Unidentified speaker: That's a lot of authority around one table.
18:35
Unidentified speaker: What medical expertise was there?
18:37
Unidentified speaker: And what does an impressive board actually prove?
18:40
Unidentified speaker: And we need to correct an oversimplification.
18:43
Unidentified speaker: Frist was a transplant surgeon.
18:45
Unidentified speaker: William Fogie, a former CDC director, also served.
18:49
Unidentified speaker: This wasn't a board with literally no medical knowledge.
18:52
Unidentified speaker: The question is whether the relevant claims were independently tested and challenged.
18:57
Unidentified speaker: Mattis' name also brings up the military claims.
19:00
Unidentified speaker: What were investors being told about that?
19:02
Unidentified speaker: The SEC said Theranos claimed its products have been deployed by the Department of Defense on battlefields in Afghanistan and on medical evacuation helicopters.
19:12
Unidentified speaker: According to the SEC, that deployment had never happened.
19:17
Unidentified speaker: That makes it sound as though the technology has already passed an enormous real-world test.
19:22
Unidentified speaker: If it's being used in a war zone, you'd assume it must work.
19:25
Unidentified speaker: Exactly.
19:26
Unidentified speaker: It's not just another impressive name, it's a claimed track record.
19:30
Unidentified speaker: Discussion about possible use or an evaluation is very different from saying a device is already being used to care for people.
19:47
Unidentified speaker: That's the scam connection.
19:49
Unidentified speaker: Ask what used by actually means.
19:52
Unidentified speaker: Was there a conversation, a study, a purchase, or routine use?
19:57
Unidentified speaker: Those aren't interchangeable.
19:59
Unidentified speaker: And a claim about deployment can be checked independently.
20:02
Unidentified speaker: There are two shortcuts there, aren't there?
20:05
Unidentified speaker: Important people believe it, that's authority.
20:08
Unidentified speaker: Other people have already invested, that's social proof, but neither tells me what anyone actually checked.
20:14
Unidentified speaker: Exactly.
20:15
Unidentified speaker: Those names made the pitch feel credible.
20:18
Unidentified speaker: That doesn't mean every director knew it was false.
20:21
Unidentified speaker: They could have been misled too.
20:23
Unidentified speaker: So her claim gets to borrow somebody else's good name.
20:26
Unidentified speaker: Is that similar to what happens when a scam spreads through people who trust one another?
20:31
Unidentified speaker: That's similar to the trust EC exploited in affinity fraud.
20:35
Unidentified speaker: The SEC describes scams that spread through groups and trusted leaders, even leaders who've been fooled themselves.
20:41
Unidentified speaker: It's a useful comparison.
20:43
Unidentified speaker: Not the formal label the verdict gave Theranos.
20:46
Unidentified speaker: I can trust my friend and still check the investment.
20:49
Unidentified speaker: How did that personal trust work alongside the invitation to invest in Theranos?
20:53
Unidentified speaker: We have a specific example from Lisa Peterson, who handled the Theranos investment for the DeVos family office.
20:59
Unidentified speaker: Trial reporting described an invitation to a small hand-picked group of families.
21:03
Unidentified speaker: The family initially contemplated $50 million and ultimately invested $100 million after meeting Holmes.
21:10
Unidentified speaker: Peterson testified that they worried too many questions would get them uninvited.
21:14
Unidentified speaker: There's the fear of missing out.
21:16
Unidentified speaker: We have that account.
21:18
Unidentified speaker: We shouldn't assume every investor face exactly the same pressure.
21:21
Unidentified speaker: So the questions that protect your money start to feel like the ones that might get you shown the door.
21:26
Unidentified speaker: Did other well-known investors add to that feeling that somebody must have checked it?
21:31
Unidentified speaker: Rupert Murdoch and the Walton family also invested, alongside the DeVos family.
21:37
Unidentified speaker: That gives the pitch another bit of social proof, but their investment tells us they said yes.
21:44
Unidentified speaker: Not that they independently proved the technology work.
21:47
Unidentified speaker: And being specially invited is flattering.
21:49
Unidentified speaker: You don't want to spoil it by seeming difficult.
21:52
Unidentified speaker: That's how I read the pressure of the invitation.
21:54
Unidentified speaker: Not something we're claiming Holmes said out loud.
21:57
Unidentified speaker: The SEC's case concerned more than $700 million raised from late 2013 through 2015.
22:05
Unidentified speaker: Not the company's entire fundraising history.
22:08
Unidentified speaker: That's the trap.
22:10
Unidentified speaker: Is this true?
22:11
Unidentified speaker: Because am I about to lose my place?
22:13
Unidentified speaker: Manufactured urgency is where common sense goes to die.
22:16
Unidentified speaker: What happens once you've already said yes?
22:19
Unidentified speaker: Then there's commitment and consistency.
22:22
Unidentified speaker: Once you've invested, or told everyone you believe in the company, it can be harder to change your mind.
22:28
Unidentified speaker: That's a common human pressure.
22:30
Unidentified speaker: Not something we can claim every Theranos investor felt.
22:34
Unidentified speaker: Because now you're asking whether you were right to back it.
22:37
Unidentified speaker: What happened when investors did start to question the story?
22:40
Unidentified speaker: Peterson testified that Holmes downplayed the negative reporting when investors asked what was going on.
22:46
Unidentified speaker: Reassurance like that can make it easier to stay with a story you already believe instead of looking at what challenges it.
22:53
Unidentified speaker: You're allowed to change your mind.
22:55
Unidentified speaker: I believed what I was told, now I know more.
22:58
Unidentified speaker: That's not disloyal, that's paying attention.
23:01
Unidentified speaker: You can see a similar pattern in relationship-length investment scams.
23:06
Unidentified speaker: Investor.gov warns about trust building, shared connections, and fear of missing out.
23:11
Unidentified speaker: It's a different setting, but the same question matters.
23:14
Unidentified speaker: Did the relationship take the place of checking the investment?
23:18
Unidentified speaker: This isn't a competition to decide which victims should have known better.
23:22
Unidentified speaker: It's a chance to notice the shortcuts a convincing story asks us to take.
23:45
Unidentified speaker: Reporting based on John Carrie Roo's work described Holmes adopting the Steve Jobs-style black turtleneck and hiring former Apple employees, including designer Anna Riola.
23:55
Unidentified speaker: Those details help explain the image surrounding the company.
24:15
Unidentified speaker: Reports about her voice need attribution, and eye contact can't establish intent.
24:20
Unidentified speaker: The claims and evidence matter more.
24:22
Unidentified speaker: Otherwise, we judge a woman's voice instead of checking the claims.
24:26
Unidentified speaker: What happened when people inside the company question those claims?
24:30
Unidentified speaker: A warning sign is when the organization stops examining the problem and starts attacking the person who reported it.
24:37
Unidentified speaker: That trade secret explanation also matters inside the company.
24:42
Unidentified speaker: Confidentiality can be legitimate, but it doesn't excuse misleading claims about what a method does.
24:48
Unidentified speaker: So not getting an answer can start to feel like proof that you found something special.
24:53
Unidentified speaker: It's too revolutionary to show you.
24:56
Unidentified speaker: That's how we're describing the pitch's logic, not quoting her.
24:59
Unidentified speaker: Not every secret is a scam, but secrecy can't grade its own homework.
25:05
Unidentified speaker: Who inside Theranos was raising concerns?
25:08
Unidentified speaker: Two people we need to name are Tyler Schultz and Erica Chung.
25:11
Unidentified speaker: They worked inside Theranos and raised concerns about the testing.
25:14
Unidentified speaker: Tyler was also the grandson of board member George Schultz, so the conflict reached into his family as well as his workplace.
25:22
Unidentified speaker: That makes it painfully personal.
25:25
Unidentified speaker: What were they seeing in the lab and how were their concerns handled?
25:29
Unidentified speaker: At a Stanford event, Chung described supervisors' responses to worrying laboratory results as gaslighting.
25:35
Unidentified speaker: Schultz described colleagues getting alarming syphilis results on Theranos machines and having their concerns dismissed.
25:42
Unidentified speaker: We're using gaslighting as Chung's account of her experience, not as a clinical diagnosis of Holmes.
25:48
Unidentified speaker: Yeah, that's important to clarify.
25:49
Unidentified speaker: This isn't therapy talk.
25:51
Unidentified speaker: This was her experience on the ground in a lab where people's lives were literally on the line.
25:57
Unidentified speaker: You see a problem and somebody above you says you're the one who doesn't understand.
26:01
Unidentified speaker: After a while, you might start questioning yourself instead of the result.
26:05
Unidentified speaker: And the result still needs checking.
26:08
Unidentified speaker: Making an employee feel small doesn't explain why the tests don't matter.
26:13
Unidentified speaker: What did the quality control problems look like in practice?
26:16
Unidentified speaker: That can sound like a dry laboratory phrase until you know what was happening.
26:21
Unidentified speaker: Chang testified that the Edison machines frequently failed quality control checks.
26:26
Unidentified speaker: Those checks used samples with known concentrations to see whether the machine returned the right result.
26:32
Unidentified speaker: She described deleting one or two outline data points to make the results appear to pass without clear rules for choosing what to remove.
26:42
Unidentified speaker: So instead of the check telling you whether the machine was dependable, the bad results could disappear from the check.
26:49
Unidentified speaker: That was the concern in her testimony.
26:51
Unidentified speaker: Handling an outlier isn't automatically improper and needs a justified method.
26:56
Unidentified speaker: Choosing which results to discard just to get a passing picture is a very different thing.
27:02
Unidentified speaker: That's selective proof.
27:04
Unidentified speaker: You show people the results that support your story and leave out the ones that might change their minds.
27:09
Unidentified speaker: In Chung described differences when the same samples were tested again.
27:13
Unidentified speaker: Conventional equipment typically gave consistent results, while the Edison's could give very different readings.
27:20
Unidentified speaker: Her concern was whether that system could be trusted with patient samples.
27:24
Unidentified speaker: We shouldn't turn her account of lab practices into a claim that Holmes personally directed every deletion.
27:30
Unidentified speaker: The everyday question is: am I seeing the full record or just the good-looking part?
27:36
Unidentified speaker: That applies to an investment pitch's claimed successes as much as to an impressive demonstration.
27:41
Unidentified speaker: Chang also testified about raising concerns with Romesh Sunny Balwani, Theranos' president and chief operating officer.
27:50
Unidentified speaker: She came away with the impression that continuing to work there meant processing patient samples without question.
27:56
Unidentified speaker: So Balwani wasn't just somebody standing beside Holmes.
28:00
Unidentified speaker: What gave him so much authority inside the company?
28:03
Unidentified speaker: He was president and chief operating officer, overseeing day-to-day operations, and he also surfed on the board.
28:10
Unidentified speaker: That put him in a position to influence how the company operated and how employees' concerns were handled.
28:16
Unidentified speaker: Zhang's account shows the pressure that could create.
28:43
Unidentified speaker: Those claims were false and misleading.
28:45
Unidentified speaker: He wasn't merely hearing the pitch.
28:48
Unidentified speaker: He helped approve the story being presented to the public.
29:01
Unidentified speaker: Right.
29:02
Unidentified speaker: But his corporate authority and his legal responsibility are separate questions.
29:07
Unidentified speaker: We should describe the conduct and then name what the jury actually convicted him of, not assume his job title proves every allegation.
29:14
Unidentified speaker: So the pressure wasn't just to believe the company, it was to keep doing the work despite your doubts.
29:20
Unidentified speaker: That's how fear about your job can make a serious concern harder to raise.
29:23
Unidentified speaker: And when fear gets added to self-doubt, speaking up gets harder.
29:27
Unidentified speaker: What kind of pressure did Schultz and Chang face?
29:30
Unidentified speaker: Trial reporting described aggressive legal pressure involving Theranos attorney David Boyce and Holmes' admission that private investigators followed former employees.
29:40
Unidentified speaker: Schultz and Chang face enormous pressure while helping expose the problem.
29:44
Unidentified speaker: And once those concerns reached a reporter, did Holmes try to stop the story itself?
29:49
Unidentified speaker: Yes.
29:50
Unidentified speaker: During cross-examination, Holmes acknowledged that she went to Rupert Murdoch to try to stop the Wall Street Journal's reporting.
29:56
Unidentified speaker: Murdoch was a Theranos investor, as well as the owner behind the journal.
30:00
Unidentified speaker: She said her effort was about preventing publication of trade secrets.
30:05
Unidentified speaker: So an investor we've already mentioned was also someone she could approach over the coverage.
30:10
Unidentified speaker: What happened to the investigation?
30:12
Unidentified speaker: John Carroo's article was published on October 15th, 2015.
30:17
Unidentified speaker: Holmes later described the company's handling of the journal investigation as a disaster.
30:23
Unidentified speaker: Whatever her explanation for intervening, the attempt to stop the reporting is something she acknowledged in court.
30:30
Unidentified speaker: That's a different kind of control from persuading an investor.
30:34
Unidentified speaker: If uncomfortable information never reaches people, they can't weigh it against the pitch.
30:39
Unidentified speaker: Right.
30:39
Unidentified speaker: That's why independent reporting matters in a case like this.
30:42
Unidentified speaker: The company shouldn't get to decide which questions outsiders are allowed to hear.
30:47
Unidentified speaker: A disagreement with reporting can be answered with evidence.
30:50
Unidentified speaker: Trying to keep it from appearing limits that outside check.
30:54
Unidentified speaker: That's no longer just trying to convince you, it's making you afraid to disagree.
30:59
Unidentified speaker: What's true gets pushed aside by what will happen to me if I speak.
31:04
Unidentified speaker: And we shouldn't judge people for being afraid.
31:06
Unidentified speaker: Challenging a powerful company can cost a lot.
31:09
Unidentified speaker: Not everyone can see the whole problem, and not everyone has a safe way to raise it.
31:14
Unidentified speaker: There's another person we need to talk about, Ian Gibbons.
31:17
Unidentified speaker: What do we know about his experience?
31:19
Unidentified speaker: Dr.
31:20
Unidentified speaker: Ian Gibbons was Theranos' chief scientist and died by suicide in 2013.
31:26
Unidentified speaker: His widow, Rochelle Gibbons, told CBS that he was distressed about the company and feared losing his job if he told the truth in an upcoming deposition.
31:34
Unidentified speaker: That's Rochelle's account.
31:36
Unidentified speaker: We can hear what she says about the pressure without claiming it explains every cause of his death.
31:41
Unidentified speaker: People under pressure deserve support, not a judgment about whether they were brave enough.
31:47
Unidentified speaker: And on the patient side, what did people experience when they relied on the tests?
31:51
Unidentified speaker: Then there's Brittany Gould.
31:53
Unidentified speaker: She testified that Therano's pregnancy hormone results led her clinician to tell her she was miscarrying.
32:00
Unidentified speaker: Hesting at another laboratory contradicted that interpretation, and she later had a healthy baby.
32:05
Unidentified speaker: She wasn't chasing a fortune.
32:07
Unidentified speaker: She wanted dependable information about a pregnancy.
32:10
Unidentified speaker: What did the other patient testimony describe?
32:13
Unidentified speaker: Another patient, Erin Tompkins, testified about an abnormal HIV antibody result and the distress it caused.
32:20
Unidentified speaker: She said she struggled to reach qualified staff at Deranos, and later testing elsewhere was negative.
32:26
Unidentified speaker: We need to distinguish an alarming screening finding from a confirmed diagnosis.
32:31
Unidentified speaker: How do we keep those patient experiences separate from the legal outcome?
32:35
Unidentified speaker: What did the jury actually decide?
32:38
Unidentified speaker: And we need to be precise about accountability.
32:40
Unidentified speaker: In January 2022, the jury convicted Holmes of one investor fraud conspiracy count and three investor wire fraud counts.
32:48
Unidentified speaker: It acquitted her on the patient-related conspiracy count.
32:52
Unidentified speaker: And three individual patient count.
32:54
Unidentified speaker: And Balwani had a separate trial.
32:56
Unidentified speaker: What was he convicted of?
32:57
Unidentified speaker: On July 7, 2022, a federal jury convicted him on all 12 counts.
33:02
Unidentified speaker: Two counts of conspiracy to commit wire fraud and ten counts of wire fraud.
33:06
Unidentified speaker: One conspiracy concerned investors, and the other concerned paying patients.
33:10
Unidentified speaker: The 10 wire fraud counts comprised six involving investors and four involving patients.
33:16
Unidentified speaker: So unlike Holmes, his convictions included the patient fraud scheme.
33:20
Unidentified speaker: What sentences did they receive?
33:22
Unidentified speaker: At his December 7, 2022 sentencing, Balwani received 155 months in federal prison, 12 years and 11 months, followed by three years of supervised release.
33:33
Unidentified speaker: The prison terms on the 12 counts ran concurrently, meaning at the same time, not one after another.
33:39
Unidentified speaker: Holmes was originally sentenced on November 18, 2022, to 135 months, 11 years and 3 months in federal prison, followed by 3 years of supervised release.
33:51
Unidentified speaker: Her convictions were three counts of wire fraud and one count of conspiracy to commit wire fraud, all concerning investors.
33:58
Unidentified speaker: Those are the original sentences imposed in 2022, not a statement of their current release date.
34:03
Unidentified speaker: Same company, separate trials, and different verdicts.
34:07
Unidentified speaker: That distinction matters just as much as the prison terms, so we don't rewrite the verdict to make the story simpler.
34:13
Unidentified speaker: We can respect patients' experiences and still describe exactly what the jury decided.
34:18
Unidentified speaker: Before the prevention checks, let's put the scam tactics into one five-item checklist.
34:23
Unidentified speaker: What did homes do that listeners might recognize in an everyday scam pitch?
34:27
Unidentified speaker: Borrowed credibility.
34:29
Unidentified speaker: The pharmaceutical logos she added to Theranos' reports weren't authorized, according to company witnesses.
34:34
Unidentified speaker: An everyday scam pitch can do the same thing.
34:36
Unidentified speaker: With impressive names and official-looking documents, make you think somebody trustworthy has checked a claim.
34:43
Unidentified speaker: Sold a breakthrough while concealing the substitute.
34:46
Unidentified speaker: Holmes acknowledged that Theranos use modified Siemens analyzers without telling partners.
34:51
Unidentified speaker: That's the bait and switch pattern.
34:52
Unidentified speaker: The story that gets you interested doesn't match what actually delivers a surface.
34:57
Unidentified speaker: Made Access feel exclusive.
34:59
Unidentified speaker: Peterson described a hampicked group of families and fear that too many questions would get them uninvited.
35:05
Unidentified speaker: That resembles the everyday don't miss your chance pitch.
35:08
Unidentified speaker: Protecting your place starts to matter more than checking the opportunity.
35:12
Unidentified speaker: Presented an impressive track record that wasn't real.
35:15
Unidentified speaker: The SEC sat there and was claimed military deployment that never happened.
35:19
Unidentified speaker: In an everyday scam, claims about prestigious customers or successful users can make an unverified product look proven.
35:26
Unidentified speaker: Ask what actually happened, not just who gets in it.
35:29
Unidentified speaker: Try to keep contrary information from recent people.
35:33
Unidentified speaker: Holmes acknowledged trying to stop the journal's reporting and described her efforts as protecting trade secrets.
35:38
Unidentified speaker: The familiar scam pattern is controlling what you hear, using secrecy and resistance to outside scrutiny to keep the pit from being tested.
35:45
Unidentified speaker: So when it comes down to it, Holmes was using the same tricks as an everyday scammer.
35:50
Unidentified speaker: Borrow somebody else's credibility, sell a story you can't verify, and make questions feel unwelcome.
35:56
Unidentified speaker: Only the packaging was different.
35:58
Unidentified speaker: A pretty blonde and a black turtleneck with a polished pitch and powerful people backing her.
36:03
Unidentified speaker: The looks weren't the scam.
36:05
Unidentified speaker: The gap between what she promised and what people could actually verify was.
36:10
Unidentified speaker: That's exactly right.
36:11
Unidentified speaker: And thanks for bringing up the black turtleneck.
36:13
Unidentified speaker: I wanted to talk about that.
36:14
Unidentified speaker: Steve Jobs famously wore a black turtleneck too.
36:17
Unidentified speaker: It became part of his signature look, and Holmes' work uniform invited that comparison.
36:22
Unidentified speaker: What was her explanation for wearing it?
36:25
Unidentified speaker: In a 2015 glamour interview, Holmes said wearing the same thing every day gave her one less thing to think about.
36:33
Unidentified speaker: She estimated she owned about 150 black turtlenecks and said she'd worn turtlenecks since childhood.
36:39
Unidentified speaker: Her explanation was that she was focused on her work, and that seriousness carried over into how she dressed.
36:47
Unidentified speaker: That's her explanation.
36:48
Unidentified speaker: I'm skeptical, but skepticism isn't proof that it's false.
36:52
Unidentified speaker: How does it compare with what Ariola described?
36:55
Unidentified speaker: Good point.
36:56
Unidentified speaker: Former Theranos designer Anna Areola later described Holmes' admiration for jobs' uniform and interest in achieving a similar look.
37:05
Unidentified speaker: That's Ariola's account, distinct from Holmes's explanation.
37:09
Unidentified speaker: The useful lesson isn't to distrust a turtleneck, it's not to mistake a familiar image of success for proof that somebody's claims are true.
37:18
Unidentified speaker: We can't undo what those families experienced, but what can listeners take from these examples before they face a convincing pitch of their own?
37:27
Unidentified speaker: Let's turn those examples into four checks you can actually use.
37:30
Unidentified speaker: Not can I spot a convincing liar, but what would let me verify this claim?
37:35
Unidentified speaker: Start with the demonstration.
37:38
Unidentified speaker: King described a cartridge going into an Edison while the testing happened downstairs on other machines.
37:43
Unidentified speaker: So what should someone watching a demo ask?
37:47
Unidentified speaker: Did the device I saw produce this result?
37:50
Unidentified speaker: Follow the whole process, not just the impressive beginning and end.
37:54
Unidentified speaker: Ask for independent testing of the actual product under the conditions in which it will be used.
38:00
Unidentified speaker: A convincing demonstration isn't the same as dependable, routine performance.
38:05
Unidentified speaker: Then there's the familiar retailer.
38:08
Unidentified speaker: You see the service in a pharmacy and think somebody must have checked it.
38:12
Unidentified speaker: How do you get past that assumption?
38:14
Unidentified speaker: Ask what was checked.
38:16
Unidentified speaker: Was an expert judging the idea, reviewing information the seller provided, or independently testing the device.
38:24
Unidentified speaker: Those aren't the same.
38:25
Unidentified speaker: A partnership tells you there's a business relationship.
38:28
Unidentified speaker: It doesn't, by itself, establish that the medical technology works.
38:32
Unidentified speaker: Third, the military claim.
38:35
Unidentified speaker: Being told something was used on a battlefield sounds like the ultimate endorsement.
38:39
Unidentified speaker: What does used by need to mean?
38:42
Unidentified speaker: Make the seller be specific.
38:44
Unidentified speaker: A conversation, a study, a purchase, and actual use in patient care are different claims.
38:50
Unidentified speaker: Ask who used it, for what purpose, and when.
38:53
Unidentified speaker: And confirm that through an independent source.
38:56
Unidentified speaker: Don't let a famous institution's name answer questions the evidence hasn't answered.
39:01
Unidentified speaker: And fourth, the quality control results.
39:03
Unidentified speaker: Chang described removing data points to make the tests appear to pass.
39:08
Unidentified speaker: How do you avoid being shown only the good-looking part?
39:11
Unidentified speaker: Ask what failed, what was left out, and why.
39:14
Unidentified speaker: Were there clear rules for excluding results, or were the rules being bent to get a pass?
39:20
Unidentified speaker: To repeat testing, give consistent answers, get someone qualified and independent to review the evidence.
39:27
Unidentified speaker: A clean-looking report means little if the inconvenient results were removed.
39:31
Unidentified speaker: And Balwani's role adds something to that fourth check, doesn't it?
39:35
Unidentified speaker: He oversaw the day-to-day work, and Chang described feeling she had to process samples without question.
39:41
Unidentified speaker: What happens to the value of those checks if people are afraid to report a problem?
39:45
Unidentified speaker: That's why we ask how concerns were handled, not just whether there's a report saying the tests passed.
39:51
Unidentified speaker: Were inconsistent results examined, or was the person raising them challenged?
39:55
Unidentified speaker: While Wani's title didn't prove the technology worked, his operational authority made the response to those concerns especially important.
40:04
Unidentified speaker: So the boss says it's fine isn't another layer of independent verification.
40:08
Unidentified speaker: It may be the same reassurance coming from somebody with power over the people doing the checking.
40:14
Unidentified speaker: Right.
40:15
Unidentified speaker: The person overseeing the work shouldn't be the only source you rely on to assess it.
40:20
Unidentified speaker: That brings us back to qualified independent review, and remembering that pressure to stay quiet doesn't resolve the underlying problem.
40:27
Unidentified speaker: So we're checking the process, what the partnership proves, the claim track record, and the full results.
40:34
Unidentified speaker: What if they tell you there's no time?
40:35
Unidentified speaker: Or that asking means you don't trust them.
40:38
Unidentified speaker: Ask for the information in writing and take time for independent review.
40:42
Unidentified speaker: If they want allow meaningful verification, walk away.
40:46
Unidentified speaker: Secrecy isn't validation.
40:48
Unidentified speaker: Titles aren't test results, and urgency isn't a reason to skip questions.
40:53
Unidentified speaker: I need time to check this is a complete sentence.
40:57
Unidentified speaker: You don't have to earn the privilege of handing over your money.
41:00
Unidentified speaker: And if someone has deceived you, that isn't a character flaw.
41:04
Unidentified speaker: So you know what?
41:06
Unidentified speaker: We've covered a lot in this episode, and we haven't even scratched the surface.
41:11
Unidentified speaker: Well, you know what that means?
41:13
Unidentified speaker: This has gotta be a two-parter.
41:15
Unidentified speaker: Yes, I agree.
41:16
Unidentified speaker: So, in Therano's episode two, we'll focus on the internal cracks, the retaliatory intimidation, and the legal reckoning that ultimately brought the whole affair down.
41:27
Unidentified speaker: We've touched on those pieces to date.
41:29
Unidentified speaker: Next time, we'll give them the time they deserve.
41:32
Unidentified speaker: Thanks for spending this time with us on Behind the Scams.
41:34
Unidentified speaker: Our goal is to make these stories useful.
41:37
Unidentified speaker: Not just to look back at what happened, but to help people ask better questions before the next convincing pitch.
41:44
Unidentified speaker: And if you've been deceived, you deserve support.
41:47
Unidentified speaker: Shame doesn't help anyone sort out what happened.
41:50
Unidentified speaker: A little space, good information, and people who will listen can make a difference.
41:55
Unidentified speaker: We're grateful for your support of the nonprofit work of the SOS Media Network and for helping bring these conversations to more people.
42:03
Unidentified speaker: We couldn't do it without you.
42:04
Unidentified speaker: Take your time, ask your questions, and join us for Theranos episode two on Behind the Scams.
42:11
Unidentified speaker: Bye for now.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3 and interpreted by Qwen3.6-35B-A3B-GGUF:UD-Q4_K_XL. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from Behind the Scams | AI Scams & Digital Deception Experts

All insights